2020年5月20日 · DNL151 is an orally available, brain-penetrant inhibitor of the leucine-rich repeat kinase 2 (LRRK2). It started out as a backup to Denali’s lead LRRK2 inhibitor, DNL201; but it is now its lead candidate after development of DNL201 was stopped in 2020.

DNL-151: 一种LRRK2抑制剂药物，由Genentech, Inc. (Genentech, Inc.)公司最早进行研发，目前全球最高研发状态为临床3期，作用机制: LRRK2抑制剂(富含亮氨酸重复的丝氨酸/苏氨酸蛋白激酶-2抑制剂)，治疗领域: 神经系统疾病,内分泌与代谢疾病，在研适应症: 帕金森病，在研 ...

Inhibition of LRRK2 kinase activity is a promising new approach to treat PD with a LRRK2 mutation and sporadic PD. DNL151 is a potent, selective, CNS-penetrant LRRK2 kinase inhibitor under investigation for treatment of PD. Method: Two studies are …

2023年2月23日 · Objective: The aim of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the potent, selective, CNS-penetrant LRRK2 inhibitor BIIB122 (DNL151) in healthy participants and patients with PD. Methods: Two randomized, double-blind, placebo-controlled studies were completed.

2023年9月28日 · Leucine-rich repeat kinase 2 inhibition with oral application of DNL151, respectively DNL201, and intrathecal administration of the antisense oligonucleotide BIIB094 in a single and multiple ascending dose study was safe and well tolerated.

2025年1月13日 · DNL151 is an orally available, brain-penetrant inhibitor of the leucine-rich repeat kinase 2 (LRRK2). It started out as a backup to Denali’s lead LRRK2 inhibitor, DNL201; but it is now is its lead candidate after development of DNL201 was stopped in 2020. (Sourced from: https://www.alzforum.org/therapeutics/dnl151)

Inhibition of LRRK2 kinase is a promising approach to treat PD with a LRRK2 mutation and sporadic PD. BIIB122/DNL151 is a potent, selective, CNS-penetrant LRRK2 kinase inhibitor under investigation for treatment of PD.

2022年6月3日 · BIIB122/DNL151 is a small molecule designed to penetrate the central nervous system (the brain and spinal cord) where it blocks LRRK2 activity. By restoring the normal activity of lysosomes, BIIB122/DNL151 may slow Parkinson’s progression.

2024年12月11日 · DNL 151 (also known as BIIB 122) is a selective and brain-penetrant small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), being developed by Denali

2019年7月4日 · Denali Therapeutics is developing DNL-151 (phase 1, in July 2019), a lead from a program of small-molecule inhibitors of LRRK2 originally licensed from Genentech, for the treatment of Parkinson’s disease. Leucine-rich repeat kinase 2 (LRRK2) is a complex signaling protein that is a key therapeutic target, particularly in Parkinson’s disease (PD).